Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hormone Refractory Prostate Cancer × bafetinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Oligodendroglioma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hormone Refractory Prostate Cancer 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 4 radium Ra 223 dichloride 2 Prednisone 2 sargramostim 1 gossypol acetic acid 1 epothilone B 1 bafetinib 1 Sunitinib 1 PE regimen 1 Mycobacterium w vaccine 1 Interleukin-2 1 Injections 1 Everolimus 1 Etoposide 1 Denosumab 1 Cyclophosphamide 1 Cisplatin 1 Carboplatin 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01215799 2011-12-15

PROACT

CytRx

Phase 2 Completed

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡